Group 1 - The core viewpoint of the article highlights the rise of Fan Daidi and her husband Yan Jianya as the new richest individuals in Shaanxi, with a combined stock value of 457 billion yuan from their holdings in Juzi Biotechnology and Triangle Defense [1][2] - Juzi Biotechnology, which specializes in recombinant collagen, has a market capitalization of 836 million HKD (approximately 773 million yuan) as of May 12, while Triangle Defense, a military enterprise, has a market capitalization of 147 million yuan [1][2] - According to the 2024 Hurun Rich List, the couple ranks 196th nationally with a wealth of 245 million yuan, placing them third among the wealthy in Shaanxi [1] Group 2 - Fan Daidi, born in January 1966, has a background in biological engineering and has held various academic positions at Northwest University, including Vice President [2] - In 2000, she developed a type of human-like collagen using genetic engineering technology, and in 2001, she applied for China's first patent for recombinant collagen [2] - Since 2019, Juzi Biotechnology has become the largest collagen professional skincare product company in China and one of the largest globally in terms of recombinant collagen production capacity [2] - In the latest annual report, Juzi Biotechnology reported a revenue of 5.539 billion yuan, a year-on-year increase of 57.2%, and a net profit of 2.062 billion yuan, up 42.1%, with a gross margin of 82.09% [2]

截至2025年5月13日 09:39，恒生医疗保健指数(HSHCI)强势上涨1.38%，成分股百济神州(06160)上涨5.16%，医脉通(02192)上涨5.15%，乐普生物-B(02157)上 涨4.67%，信达生物(01801)，翰森制药(03692)等个股跟涨。恒生医疗ETF(513060)上涨1.72%，最新价报0.47元。流动性方面，恒生医疗ETF盘中换手 3.08%，成交3.05亿元。拉长时间看，截至5月12日，恒生医疗ETF近1月日均成交13.50亿元，排名可比基金第一。 德邦证券指出，AI的发展带动AI医疗的全面普及，大量医疗企业接入DS、华为等AI模型，开始摸索AI在医疗的应用。我们认为，1）拥有大量底层病人数据 的企业将有很大应用落地空间，2）拥有医保数据的企业有望深入应用AI，3）AI制药继续升级，建议关注此类公司。此外，积极关注1）创新药及其产业链 的技术革新与BD潜力；2）有业绩，基本面出现拐点的企业。 西南证券表示，2025年2月，国产大模型DeepSeek-R1全面开源与多领域适配，AI医疗迈入技术融合与行业重构的新阶段，DeepSeek的多模型协同能力成为 行业新范式。这种" ...

Core Insights - The performance of domestic beauty companies in China is showing significant divergence, with some achieving remarkable growth while others face declines, indicating a reshaping of the market landscape [1][4][42] Group 1: Company Performance - Proya has become the first domestic beauty company to enter the 10 billion yuan club, with a revenue of 10.778 billion yuan, growing by 21.04% [2] - Other companies like Shangmei and Juzi Biological also reported substantial revenue increases of 62.08% and 57.17% respectively, while Shanghai Jahwa experienced a revenue decline of 13.93% [2][3] - Six beauty companies have revenues exceeding 5 billion yuan, suggesting that this threshold will soon become a significant benchmark for the top 10 domestic beauty brands [1] Group 2: Profitability Trends - Juzi Biological leads in profitability with a profit of 2.062 billion yuan, up 42.06%, while Proya's profit reached 1.552 billion yuan, growing by 30% [3] - In contrast, Shanghai Jahwa reported a loss of 833 million yuan, marking a 266.60% decline, highlighting the stark differences in profitability among companies [3][11] Group 3: Market Dynamics - The current market dynamics indicate a shift towards efficacy-driven products, with companies that successfully launched standout products seeing better performance [4][5] - The competition is intensifying, with new entrants emerging and established brands needing to adapt to changing consumer preferences and market trends [7][30] Group 4: R&D and Strategic Focus - Companies are increasingly focusing on R&D, with most reporting a rise in R&D expenditures, indicating a strategic shift towards innovation and efficacy [20][21] - The trend of acquisitions and investments in technology is becoming a key strategy for companies aiming to enhance market share and scale [23][24] Group 5: Emerging Opportunities - The male skincare market is growing rapidly, presenting new opportunities for brands to capture this segment [36] - The aging population is creating demand for products targeting older consumers, which remains largely untapped [39] - As online sales plateau, brands are shifting focus to offline channels, indicating a potential new battleground for market share [40]

西北大学官网资料显示，范代娣出生于1966年1月，今年59岁，陕西蒲城人，从华东理工大学生物工程 系博士毕业后，便进入西北大学工作，历任西北大学化工学院副院长、院长。今年4月，范代娣出任西 北大学党委委员、常委、副校长。 2000年，范代娣用基因工程技术高密度发酵生产的一种类人胶原蛋白宣告问世。2001年，范代娣申请了 中国第一个重组胶原蛋白发明专利——"一种类人胶原蛋白及其生产方法"。同年9月，范代娣夫妻二人 创立了巨子生物基因技术股份有限公司。 自2019年起，巨子生物成为中国最大的胶原蛋白专业皮肤护理产品公司，也是全球范围内拥有最大重组 胶原蛋白产能的企业之一。2022年11月，该公司在港股上市。 年报显示，去年，巨子生物实现营收55.39亿元，同比增长57.2%；实现归属净利润20.62亿元，同比增 长42.1%，公司毛利率达到82.09%。 今年4月上任的西北大学女副校长范代娣及其丈夫以持股市值超450亿元的身价，成为新一任陕西首富。 目前，范代娣及其丈夫严建亚名下有巨子生物(02367.HK)和三角防务(300775)两家上市公司。截至5月 12日收盘，巨子生物的市值为836亿港元(约合人民币77 ...

Investment Rating - The investment rating for Giant Biogene Holding Co Ltd is Overweight [6] Core Insights - The report highlights that Giant Biogene (GB) has seen limited positive impact on its P&L from supportive policies and subsidies from online platforms, as some platforms refocus on leading brands over white labels [2] - GB has expanded its product offerings to Hong Kong and Southeast Asia, utilizing social media for branding and adjusting product sizes to match local purchasing power [3] - The Mi Xiu series targets premium customers with an average selling price (ASP) of Rmb500-800, with plans for further expansion into medical aesthetics and online channels [4] - The Collagen Stick 2.0 has received encouraging sales feedback and is a key product for upcoming promotions, with expectations for improved gross profit margins [9] - The company plans to use US$300 million from share issuance primarily for overseas expansion and potential mergers and acquisitions in cosmetics, medical aesthetics, and healthcare [9] Financial Metrics - The price target for Giant Biogene is set at HK$85.00, representing a 7% upside from the current price of HK$79.20 [6] - Projected revenue growth shows an increase from Rmb5,539 million in 2024 to Rmb10,523 million by 2027, with EBITDA expected to rise from Rmb2,502 million to Rmb4,507 million in the same period [6] - The estimated EPS is projected to grow from Rmb2.06 in 2024 to Rmb3.67 in 2027, indicating a strong growth trajectory [6]

Investment Rating - The report maintains a "Buy" rating for Giant Biogene and Shanghai Jahwa, reflecting their potential for growth and turnaround [11][26]. Core Insights - The China beauty sector is showing signs of stabilization, with demand shifting from negative year-over-year (yoy) growth to a flat performance, particularly noted during Women's Day [1]. - Onshore sales growth in 1Q25 re-accelerated to 3.2% yoy, surpassing the full-year estimate of 1.2% yoy, although this was countered by a decline in the DFS channel [1]. - The sector has experienced a 50% rerating, with the 12-month price-to-earnings (PE) ratio moving from 20x to 30x, indicating a recovery towards mid-cycle valuation levels [1][7]. Summary by Sections Sales Performance - The covered companies in the China cosmetics sector reported mixed results for 2024/1Q25, with most missing sales expectations except for Giant Biogene, which outperformed due to effective cost management [2][25]. - The average selling expenses ratio decreased by 6.8 percentage points yoy in 4Q24 and 3.7 percentage points yoy in 1Q25, indicating improved cost discipline across the sector [2][25]. Competitive Landscape - Local brands are gaining market share, with emerging leaders like Giant Biogene, Marubi, and Chicmax achieving over 30% sales growth, while global brands are pulling back on promotions to focus on quality growth [3][13]. - The premium segment remains largely dominated by global brands, but local brands are expected to capture more market share over the next 5-10 years [6]. Valuation Trends - The beauty sector's valuation has rebounded to around 30x PE, reflecting a recovery from downcycle lows and aligning more closely with global peers [7][8]. - Limited valuation upside is anticipated as the sector stabilizes at mid-cycle levels, with potential idiosyncratic rerating drivers emerging from new product categories and brand expansions [8]. Catalysts for Growth - Key upcoming events include the 618 shopping festival and increased activity in the medical aesthetics space, which could provide growth opportunities for companies like Giant Biogene [9][10]. - The report highlights the importance of effective execution and brand expansion as critical factors for sustained growth in the sector [8][11]. Stock Preferences - The report favors emerging leaders such as Giant Biogene and Shanghai Jahwa, while maintaining a neutral stance on MGP, Proya, and Botanee due to concerns over growth visibility and execution [11][26]. - A sell rating is assigned to Bloomage, reflecting challenges in revitalizing its cosmetics business amid intensified competition [11][26].

Core Insights - The domestic beauty industry in China is expected to undergo a significant restructuring by 2025, with companies showing rapid growth driven by strong single-brand performance and a shift in consumer focus towards verified efficacy rather than just ingredient composition [2][10] Revenue Performance - Proya has become the first domestic beauty company to surpass 10 billion yuan in revenue for 2024, achieving 10.779 billion yuan, maintaining its top position [4] - Shangmei Co. has shown the fastest revenue growth, with a 62.1% increase from 4.191 billion yuan in 2023 to 6.793 billion yuan in 2024, rising from sixth to second place among the sample companies [3][4] - Other notable companies include Betaini with 5.736 billion yuan, Shanghai Jahwa with 5.679 billion yuan, and Juzhibio with 5.54 billion yuan, all showing varying degrees of growth [4] Brand Performance - Shangmei's brand Han Shu generated nearly 5.6 billion yuan in 2024, accounting for 82.3% of the group's total revenue, with a growth rate of 73.7% [5] - Juzhibio's brand Kefu Mei achieved 4.54 billion yuan in revenue, representing 82% of its total revenue, with a growth rate of 62.9% [6] Market Trends - The popularity of hyaluronic acid is declining, while "recombinant collagen" is emerging as a lucrative ingredient, reflecting a shift in consumer preferences towards efficacy-driven skincare [7][9] - The market is witnessing a transition from ingredient-focused to efficacy-focused products, with companies like Proya leveraging this trend to capture market share [10][11] R&D and Investment - There is a growing disparity between revenue growth and R&D investment among companies, with Proya's R&D expenditure at only 1.95% of total revenue, the lowest among the sample companies [12] - In contrast, Juzhibio, despite its rapid revenue growth, has a low R&D investment ratio of 1.9%, indicating a potential risk in long-term sustainability [12] Industry Dynamics - The beauty industry is moving towards a phase where product efficacy and R&D capabilities are becoming critical competitive factors, as opposed to relying solely on marketing [13] - The gap in revenue between leading and mid-tier companies is widening, suggesting a trend towards market consolidation and structural transformation within the industry [13]

Core Points - The Shanghai Composite Index decreased by 0.30%, while the China Securities Hong Kong Mid-Cap Select Index increased by 0.38%, closing at 2305.91 points with a trading volume of 16.681 billion yuan [1] - The China Securities Hong Kong Mid-Cap Select Index has seen a rise of 10.27% over the past month, 5.76% over the past three months, and 7.80% year-to-date [1] - The index consists of 100 medium-sized securities selected from the Hong Kong market, reflecting the overall performance of medium-sized securities listed on the Hong Kong Stock Exchange [1] Index Holdings - The top ten weighted stocks in the China Securities Hong Kong Mid-Cap Select Index are: Pop Mart (6.77%), China Telecom (3.42%), CITIC Bank (2.87%), China Pacific Insurance (2.72%), CanSino Biologics (2.66%), China Tower (2.37%), Kingdee International (2.09%), Genscript Biotech (1.82%), CITIC Securities (1.79%), and Bilibili-W (1.76%) [1] - The index's holdings are entirely composed of stocks listed on the Hong Kong Stock Exchange, with a 100% allocation [1] Industry Breakdown - The industry composition of the index sample includes: Consumer Discretionary (19.26%), Industrials (12.52%), Financials (11.84%), Information Technology (9.83%), Communication Services (9.25%), Healthcare (8.72%), Consumer Staples (7.59%), Utilities (7.41%), Materials (5.29%), Real Estate (5.04%), and Energy (3.25%) [2] - The index sample is adjusted semi-annually, with adjustments occurring on the next trading day after the second Friday of June and December [2] - A buffer zone is established for sample adjustments, prioritizing the retention of older samples ranked between 81 and 220, with specific procedures for handling delistings, mergers, and other corporate actions [2]

Core Viewpoint - The article discusses the rise of Fan Daidi and her husband Yan Jianya as the new richest couple in Shaanxi, primarily due to their holdings in Juzi Biological and Triangle Defense, with a combined market value of nearly 900 billion yuan [2][9]. Group 1: Personal Background and Wealth - Fan Daidi holds a stock value of 443 billion yuan and has recently become the richest person in Shaanxi [2][5]. - The couple's daughter, Yan Yubo, has been rigorously trained and holds multiple financial certifications, currently serving as the secretary and executive director of Juzi Biological, with a salary increase from 140,000 yuan in 2023 to 360,000 yuan in 2024 [3][16]. Group 2: Company Overview - Juzi Biological - Juzi Biological, a leader in the field of recombinant collagen, has seen its revenue grow from 9 billion yuan in 2019 to 55 billion yuan in 2024, marking a fivefold increase over five years [18]. - The company has a projected revenue of 45.4 billion yuan in 2024, with a year-on-year growth of 62.9%, and a gross margin of 82% [17][21]. - Juzi Biological has raised a total of 45.6 billion yuan through various financing rounds since its IPO in 2022, while distributing 2.3 billion yuan in dividends to the Fan family [25] [24]. Group 3: Company Overview - Triangle Defense - Triangle Defense, which specializes in aerospace and military components, has a market value exceeding 100 billion yuan, with Yan Jianya controlling 16.09% of the shares [26][27]. - The company has experienced significant revenue growth from 4.7 billion yuan in 2018 to 24.9 billion yuan in 2023, but has faced a decline in 2024 due to reduced orders from major clients [28]. - Triangle Defense is currently under regulatory scrutiny for various management issues, which could impact its future performance [28].

Summary of the Conference Call Records Industry Overview - The beauty and personal care industry is experiencing an increase in penetration rates and rising prices, showing stronger growth compared to traditional food and beverage sectors, leading new consumption trends [1][7] - Domestic brands are rapidly rising in the beauty and personal care market, replacing foreign brands, particularly Japanese and Korean brands, which are showing significant declines [1][3] Key Financial Performance - **Personal Care Segment**: - 2024 revenue growth of 19% and net profit growth of 25% - Q1 2025 revenue growth of 29% and profit growth of 13%, driven by product innovation and Douyin channel [1][6] - **Medical Aesthetics Segment**: - 2024 revenue growth of 16% and net profit growth of 22% - Q1 2025 revenue and profit remained flat, with significant internal differentiation [1][9] - **Cosmetics Industry**: - 2024 revenue growth of 11% and net profit decline of 9% (11% growth after excluding anomalies) - Some companies like Juzhi Biotechnology and Mao Ge Ping performed exceptionally well [1][10] Channel Performance - Douyin channel is noted for its dual role in marketing and sales, with high initial costs but potential for improved profitability as brand influence expands to other channels [4][8] - In April 2025, beauty brands on Douyin showed strong performance, with several brands achieving over 100% growth [11] Company-Specific Insights - **Ruo Yuchen**: - Q1 2025 revenue and profit growth exceeded 200% for its free brand and over 150% for its household cleaning brand [12] - **Deng Kang Oral Care**: - Q1 2025 revenue and profit growth of 15%-20%, with online channels showing over 200% growth [14] - **Polaire**: - Q1 2025 saw unexpected profit growth due to improved gross margins and optimized sales expenses [16] - **Mao Ge Ping**: - April 2025 Douyin channel growth of over 30% [17] - **Perfect Bio**: - Q1 2025 revenue growth of 28% and net profit close to 30% [18] - **Runben**: - Q1 2025 revenue growth of 44%, with a focus on new product launches [19] Market Trends and Investment Recommendations - The beauty and personal care sector is expected to continue leading new consumption trends, with investment strategies focusing on companies with strong innovation capabilities and those showing positive changes [1][7][26] - Recommended stocks include Ruo Yuchen, Deng Kang Oral Care, and Runben in the personal care segment, and high-end domestic brands like Mao Ge Ping and companies in the collagen segment like Juzhi Biotechnology [26] Additional Insights - The beauty and personal care sector is more sensitive to product demand, innovation, and channel changes compared to other consumer goods, providing a natural premium and innovation potential [24] - The overall market for personal care, beauty, and medical aesthetics is expected to show strong growth, driven by product innovation and structural opportunities [25]